394 related articles for article (PubMed ID: 19772802)
1. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
Wipfler-Freibmuth E; Dejaco C; Duftner C; Gaugg M; Kriessmayr-Lungkofler M; Schirmer M
Clin Exp Rheumatol; 2009; 27(4):658-60. PubMed ID: 19772802
[TBL] [Abstract][Full Text] [Related]
2. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
[TBL] [Abstract][Full Text] [Related]
3. [Rasburicase (Fasturtec)].
Vogt B; Gugger M; Frey FJ
Ther Umsch; 2004 Sep; 61(9):579-82. PubMed ID: 15493120
[TBL] [Abstract][Full Text] [Related]
4. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
5. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.
Richette P; Brière C; Hoenen-Clavert V; Loeuille D; Bardin T
J Rheumatol; 2007 Oct; 34(10):2093-8. PubMed ID: 17896799
[TBL] [Abstract][Full Text] [Related]
6. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
7. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Kamatani N; Hosoya T
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
[No Abstract] [Full Text] [Related]
8. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
[TBL] [Abstract][Full Text] [Related]
9. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
10. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
Oldfield V; Perry CM
Drugs; 2006; 66(4):529-45. PubMed ID: 16597166
[TBL] [Abstract][Full Text] [Related]
11. Rasburicase in the treatment of hyperuricemia of newborns.
Ghirardello S; Ardissino G; Mastrangelo A; Mosca F
Pediatr Nephrol; 2010 Sep; 25(9):1775; author reply 1777. PubMed ID: 20376501
[No Abstract] [Full Text] [Related]
12. Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT).
Christensen HD; Sheta HM; Morillon MB; Hansen IM
Am J Case Rep; 2016 Jul; 17():494-8. PubMed ID: 27418121
[TBL] [Abstract][Full Text] [Related]
13. [Rasburicase for tophaceus gout treatment].
Ribeiro A; Bogas M; Costa J; Costa L; Araújo D
Acta Reumatol Port; 2009; 34(3):551-4. PubMed ID: 19820680
[TBL] [Abstract][Full Text] [Related]
14. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
15. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Wortmann RL; Macdonald PA; Hunt B; Jackson RL
Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
[TBL] [Abstract][Full Text] [Related]
16. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
[No Abstract] [Full Text] [Related]
17. [Hyperuricemia and gout: therapeutic indications].
Pawlotsky Y
Rev Prat; 1994 Jan; 44(2):206-9. PubMed ID: 8178077
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and rationale for uricase use in patients with gout.
Schlesinger N; Pérez-Ruiz F; Lioté F
Nat Rev Rheumatol; 2023 Oct; 19(10):640-649. PubMed ID: 37684360
[TBL] [Abstract][Full Text] [Related]
19. Critical revision of the medical treatment of gout in Brazil.
Azevedo VF; Lopes MP; Catholino NM; Paiva EDS; Araújo VA; Pinheiro GDRC
Rev Bras Reumatol Engl Ed; 2017; 57(4):346-355. PubMed ID: 28743362
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
